Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Patrick S. Phelan, Mary C. Politi, PhD, and Christopher J. Dy, MD, MPH
During immediate and long-term recovery periods, decisions must account for patients’ personal goals and possible clinical outcomes and should clarify what recovery means.
AMA J Ethics. 2020;22(5):E380-387. doi:
10.1001/amajethics.2020.380.
A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches.
AMA J Ethics. 2020;22(8):E695-701. doi:
10.1001/amajethics.2020.695.